To treat heterogeneous glial tumors, the blockage of immune checkpoint molecules like PD-1 has been challenging, but at least one problem was identified and tackled; namely, that the timing of administration of these inhibitors impaired their efficacy [34]. The gene discussed is PDCD1; the disease is glioma.